亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron ( PF ‐06882961), an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, in Japanese adults with type 2 diabetes mellitus

耐受性 药代动力学 医学 兴奋剂 药效学 不利影响 内科学 药理学 受体
作者
Ryosuke Ono,Kenichi Furihata,Yoshihiko Ichikawa,Yoshiomi Nakazuru,Arthur J. Bergman,Donal N. Gorman,Aditi R. Saxena
出处
期刊:Diabetes, Obesity and Metabolism [Wiley]
卷期号:25 (3): 805-814 被引量:39
标识
DOI:10.1111/dom.14928
摘要

AIMS: This study investigated the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), which is a novel, oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese participants with type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: This phase 1, randomized, double-blind, placebo-controlled, parallel-group study enrolled adult Japanese participants with T2DM inadequately controlled on diet and exercise. Participants received twice-daily oral doses of placebo or multiple ascending doses of danuglipron titrated to 40, 80 or 120 mg twice daily over 8 weeks. The primary outcome was the safety and tolerability of danuglipron. Secondary and exploratory outcomes included plasma pharmacokinetics, glycaemic parameters and body weight. RESULTS: In the 37 participants randomized, the most common treatment-emergent adverse events were nausea, vomiting, abdominal discomfort, diarrhoea and headache. Most treatment-emergent adverse events were of mild or moderate intensity. Dose-proportional increases in danuglipron exposure parameters were observed at steady state (Day 56). Significant reductions from baseline were observed with danuglipron on Day 56 for mean daily glucose [least squares mean (90% confidence interval) placebo-adjusted difference of up to -67.89 (-88.98, -46.79) mg/dl] and on Day 57 for fasting plasma glucose [up to -40.87 (-53.77, -27.98) mg/dl], glycated haemoglobin [up to -1.41% (-2.01%, -0.82%)] and body weight [up to -1.87 (-3.58, -0.17) kg]. CONCLUSIONS: In Japanese adults with T2DM, danuglipron exhibited dose-proportional increases in plasma exposure at steady state and robustly reduced glycaemic parameters and body weight after 8 weeks of dosing, with a safety profile consistent with the mechanism of action.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
生动雨安完成签到,获得积分10
7秒前
阿双完成签到,获得积分10
8秒前
10秒前
xccccccc发布了新的文献求助10
16秒前
Lucas的应助被amiee采纳,获得10
30秒前
小蘑菇的应助被令狐大侠采纳,获得10
34秒前
Maestro_S的应助被令狐大侠采纳,获得30
34秒前
科目三的应助被令狐大侠采纳,获得10
34秒前
Owen的应助被令狐大侠采纳,获得10
34秒前
科研通AI6.2的应助被令狐大侠采纳,获得10
34秒前
34秒前
科研通AI6.3的应助被令狐大侠采纳,获得10
34秒前
科研通AI65的应助被令狐大侠采纳,获得10
34秒前
科研通AI6.3的应助被令狐大侠采纳,获得10
34秒前
李爱国的应助被令狐大侠采纳,获得30
34秒前
整齐的天问完成签到,获得积分10
42秒前
小蘑菇的应助被Onebyby采纳,获得10
54秒前
烟花的应助被cfyoung采纳,获得10
1分钟前
打打的应助被cfyoung采纳,获得10
1分钟前
1分钟前
852的应助被cfyoung采纳,获得10
1分钟前
alex的应助被cfyoung采纳,获得10
1分钟前
syvshc的应助被cfyoung采纳,获得10
1分钟前
syvshc的应助被cfyoung采纳,获得10
1分钟前
alex的应助被cfyoung采纳,获得10
1分钟前
Jasper的应助被cfyoung采纳,获得10
1分钟前
syvshc的应助被cfyoung采纳,获得10
1分钟前
syvshc的应助被cfyoung采纳,获得10
1分钟前
瘦瘦的广缘完成签到,获得积分10
1分钟前
1分钟前
1分钟前
感动的仇天完成签到,获得积分10
1分钟前
kbcbwb2002完成签到,获得积分0
1分钟前
叶子头很铁的应助被LJH采纳,获得10
1分钟前
英俊的铭的应助被令狐大侠采纳,获得10
1分钟前
机智的白卉的应助被令狐大侠采纳,获得10
1分钟前
科研通AI6.2的应助被令狐大侠采纳,获得10
1分钟前
今后的应助被令狐大侠采纳,获得10
1分钟前
科研通AI65的应助被令狐大侠采纳,获得10
1分钟前
科研通AI6.3的应助被令狐大侠采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185124
求助须知:如何正确求助?哪些是违规求助? 9574047
关于积分的说明 21834014
捐赠科研通 7782575
什么是DOI,文献DOI怎么找? 3434500
关于科研通互助平台的介绍 2558743
邀请新用户注册赠送积分活动 2481201